7147 results for "canc*"

in 12.17 milliseconds.

• Whole Genome sequencing of colorectal cancer patients (SG-BULK-2)

  Whole Genome sequencing of colorectal cancer patients (SG-BULK-2)

  Dataset EGAD00001008574

• Tumour sample for patient SA276

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA276

  Dataset EGAD00001009182

• Tumour sample for patient SA599

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA599

  Dataset EGAD00001009203

• Tumour sample for patient SA655

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA655

  Dataset EGAD00001009207

• Normal sample for patient SA402

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA402

  Dataset EGAD00001009232

• Tumour sample for patient SA283

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA283

  Dataset EGAD00001009184

• Tumour sample for patient SA592

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA592

  Dataset EGAD00001009198

• Tumour sample for patient SA595

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA595

  Dataset EGAD00001009200

• Cholangiocarcinoma

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting two datasets that contain NGS files from gastrointestinal rare cancers (n=119): - Dataset 2 (87 patients): Intra-hepatic cholangiocarcinoma (n=47), Extra-hepatic, cholangiocarcinoma (n=16), Not specified Cholangiocarcinoma (n=9), Small bowel adenocarcinoma (n=6) and other rare GI cancer (n=9)

  Dataset EGAD00001008968

• Normal sample for patient SA404

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA404

  Dataset EGAD00001009233

• Normal sample for patient SA535

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA535

  Dataset EGAD00001009235

• Normal sample for patient SA665

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA665

  Dataset EGAD00001009252

• Tumour sample for patient SA279

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA279

  Dataset EGAD00001009183

• Tumour sample for patient SA398

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA398

  Dataset EGAD00001009188

• Normal sample for patient SA671

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA671

  Dataset EGAD00001009256

• Dataset for soft_tissue_tumor-WHOLE_GENOME

  Rare cancer sequencing data of 142 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired

  Dataset EGAD00001008900

• MutWP5: CRUK Mutographs of Cancer: Breast: Reduction Mammoplasty (Exome)

  Sequencing of LCM-derived microbiopsies from 10 women who underwent reduction mammoplasty. Goal to assess the mutational burden, spectrum, and clonal dynamics within the tissue. Exome data will be used as a driver and clonality screen, highly clonal or driver-containing samples will subsequently be sent for whole-genome sequencing. Results from this portion of the study will be compared to women who are BRCA1/2 germline carriers and those with cancer. . This dataset contains all the data available for this study on 2023-03-08.

  Dataset EGAD00001010110

• Tumour sample for patient SA593

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA593

  Dataset EGAD00001009199

• Tumour sample for patient SA609

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009262

• Tumour evolvability metrics predict recurrence in advanced localised prostate cancer (normal data)

  There is a need for quantitative measurements of evolutionary metrics in controlled clinical trials with long term follow-up information. This is particularly true in advanced localised prostate cancer, which can recur more than a decade after diagnosis. Here we mapped genomic intra-tumour heterogeneity in 642 tumour samples from 114 patients who took part in the IMRT and DELINEATE clinical trials, for which full clinical information and 12y median follow-up was available. We concomitantly assessed phenotypic (morphological) heterogeneity using Deep Learning in 1,923 histological sections from 250 IMRT patients (fully overlapping with the genetic set). This study shows that combining genomics with AI-aided histopathology in clinical trials leads to novel clinical biomarkers. This EGA repository contains data produced from tumour samples using low coverage whole genome sequencing and a prostate cancer specific gene panel data following compression of unique molecular identifiers.

  Dataset EGAD00001010295

• sWGS of core biopsies from localized breast cancer patients

  Paired end shallow whole genome sequencing (sWGS) data for the identification of genomewide somatic copy number alterations (SCNA) and the estimation of tumor fractions.

  Dataset EGAD00001008397

• MutWP5: CRUK Mutographs of Cancer: BRCA Carriers (WG)(Novaseq)

  Sequencing of LCM-derived microbiopsies from 20 women who underwent risk-reducing reduction mastecomies due to germline BRCA1/2. Goal to assess the mutational burden, spectrum, and clonal dynamics within the tissue. Exome data will be used as a driver and clonality screen, highly clonal or driver-containing samples will subsequenctly be sent for whole-genome sequencing. Results from this poriton of the study will be compared to women who had cosmetic breast reduction surgeries and those with cancer. . This dataset contains all the data available for this study on 2023-03-08.

  Dataset EGAD00001010112

• Normal sample for patient SA605

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009218

• Normal sample for patient SA609

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009219

• Sperm sequencing reveals extensive positive selection in the human germline -TargetedNanoSeq

  Mutations that occur during human ageing in the cell lineages of sperm or eggs have the potential to be transmitted to offspring. In males, positive selection of driver mutations during spermatogenesis is known to increase the birth prevalence of certain developmental disorders and cancer predisposition syndromes. However, direct observation of the scope of this selection in sperm has been limited by the error rates of sequencing technologies. Using the duplex sequencing method known as NanoSeq, we sequenced bulk sperm samples from individuals aged 24 to 75 years. Our findings revealed a linear accumulation mutations per year and mutational signatures consistent with pedigree studies. Deep targeted and deep exome NanoSeq of sperm samples identified genes subject to significant positive selection in the male germline, which are linked to diverse cellular pathways including RAS/MAPK and BMP signaling. Strikingly, nearly all positively selected genes are associated with developmental or cancer predisposition disorders in children. We find that this effect drives an elevated risk of known likely disease-causing mutations in sperm across a wide age range. This implies that the disorders attributed to these genes likely exhibit elevated birth prevalence in human populations, particularly among older fathers. These findings shed light on the dynamics of germline mutations and highlight an increased disease risk for children born to fathers of advanced age.

  Dataset EGAD00001015591